


TheravanceFacsimile Cover Sheet

*Filed
by official
FAX
3/18/02*

To:	Examiner Garcia
Company:	USPTO
Telephone:	703-308-0065
Fax:	703-746-5246
From:	Jeff Hagenah
Company:	Theravance, Inc.
(formerly Advanced Medicine, Inc.)	
Telephone:	650-808-6406
Fax:	650-808-6078
Date:	April 11, 2002
# of pages:	13
(including this page)	

If there are any problems in receiving this transmission, please call (650) 808-6000

Comments: Examiner Garcia:

Attached is a copy of the response filed on March 18, 2002 for U.S. Serial No. 09/457,926. I would like to discuss this response with you during the interview scheduled for April 18th, at 10:00 am. Thanks.

Jeff

Notice of Confidentiality

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

PRIVILEGED AND CONFIDENTIAL

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. (703) 872-9306, on the date shown below:

Dated: 3-18-02

By: 
Jeffrey A. Hagenah, Reg. No. 35,175

Patent
Attorney's Docket No. 032367-449 (AMI-061-R2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Burton CHRISTENSEN, et al.)
Application No.: 09/457,926) Group Art Unit: 1627
Filed: December 8, 1999) Examiner: M. Garcia
For: NOVEL ANTI-BACTERIAL AGENTS)

24/C
S/OPP
4-19-02

REPLY AND AMENDEMNT PURSUANT TO 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Reply and Amendment is being filed in response to the Office Action (Paper No. 22) mailed on December 18, 2001, for the above-identified patent application. In response to the Office Action, entry of the following amendments is respectfully requested.

In the Claims:

Please amend Claim 50 as follows:

50. (Amended) The compound according to Claim 41, wherein L" is a vancomycin moiety which is attached to the linker at the amino terminus of the vancomycin moiety.